A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

Phase 3 Completed 893 enrolled Actavis Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.

Timeline

Start: 2014-06
Primary completion: 2014-09
Completion: 2014-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tazarotene	Small molecule	0.1 %	Topical

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

Summary

Timeline

Drugs

Indications